 |
0 Diseases |  |
33 Trials |
|
33 Trials |  |
2235 News |  |
| «12...25262728293031323334353637» |
- | Preclinical, Journal: Chronic benzodiazepine suppresses translocator protein and elevates amyloid β in mice. (Pubmed Central) - Apr 30, 2019
Old cBZD-mice also showed an increase in mitochondrial membrane swelling and a decrease in mitochondrial respiration. These data suggest that cBZD exacerbates motoric aging in a manner that involves diminished TSPO, elevated Aβ, and mitochondrial damage.
- ||| lorazepam / generics
Class 4 @MHRAmedicines Alert – Ativan 4mg/1ml Solution for injection (Lorazepam) (Pfizer Limited) Caution in use https://t.co/7EPIoxtgno (Twitter) - Apr 24, 2019
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation (clinicaltrials.gov) - Apr 19, 2019
P=N/A, N=172, Recruiting, Sponsor: University of Twente
These data suggest that cBZD exacerbates motoric aging in a manner that involves diminished TSPO, elevated Aβ, and mitochondrial damage. Trial completion date: Sep 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
- | lorazepam / generics
Clinical, Reimbursement, Journal: Continuity of treatment with benzodiazepines in dementia patients: an analysis of German health insurance claims data. (Pubmed Central) - Apr 19, 2019
The treatment with BZD was not discontinued in a large proportion of dementia patients, increasing the risk of adverse events. Physicians' awareness of avoiding BZD should be improved and further evidence for the appropriate treatment of psychiatric symptoms in dementia (e.g. sleep disturbances, anxiety) is required.
- | lorazepam / generics
Journal: Comparative Study Between Oral Lorazepam and Diazepam as Sedation in Oral and Maxillofacial Surgery. (Pubmed Central) - Apr 19, 2019
The study concluded that lorazepam showed more advantages than diazepam as well as patient's preference and satisfaction. However, postoperative recovery with lorazepam was longer than diazepam.
- | lorazepam / generics, amisulpride / generics
Journal: Response of Catatonia to Amisulpride and Lorazepam in an Adolescent with Schizophenia. (Pubmed Central) - Apr 19, 2019
However, postoperative recovery with lorazepam was longer than diazepam. No abstract available
- | lorazepam / Generic mfg.
Trial completion date, Trial primary completion date: TAAT: Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome (clinicaltrials.gov) - Apr 17, 2019
P4, N=28, Recruiting, Sponsor: University of Colorado, Denver
No abstract available Trial completion date: Mar 2019 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2020
- | carbamazepine / generics
Journal: Removal of pharmaceutically active compounds from synthetic and real aqueous mixtures and simultaneous disinfection by supported TiO/UV-A, HO/UV-A, and TiO/HO/UV-A processes. (Pubmed Central) - Apr 17, 2019
...In this study, the degradation of alprazolam, clonazepam, diazepam, lorazepam, and carbamazepine was evaluated through TiO/UV-A, HO/UV-A, and TiO/HO/UV-A, using sunlight and artificial irradiation...The combination of both processes was shown to be an adequate approach, since removal increased up to 90%. HO/UV-A was used for disinfecting the aqueous matrices, while mineralization was obtained by TiO-photocatalysis.
- | lorazepam / Generic mfg.
Enrollment closed: Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care (clinicaltrials.gov) - Apr 10, 2019
P2, N=120, Active, not recruiting, Sponsor: Maria Pacella
HO/UV-A was used for disinfecting the aqueous matrices, while mineralization was obtained by TiO-photocatalysis. Not yet recruiting --> Active, not recruiting
- | lorazepam / generics
Journal: Catatonia is not schizophrenia and it is treatable. (Pubmed Central) - Apr 10, 2019
Eighty percent of the patients are relieved by the use of barbiturates or benzodiazepines, while in those who fail, an improvement is achieved by electroconvulsive therapy (ECT). With more than 60years of use in catatonic patients, ECT has proven to be an effective and safe tool for the treatment of this frequent and sometimes forgotten syndrome.
- |||||| lorazepam / Generic mfg.
New trial: LORA-PITA IV General Investigation (clinicaltrials.gov) - Apr 5, 2019
P, N=200, Not yet recruiting, Sponsor: Pfizer
- | ketamine / Generic mfg., phenobarbital / Generic mfg.
Trial initiation date: PKAT: Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine (clinicaltrials.gov) - Apr 4, 2019
P4, N=222, Not yet recruiting, Sponsor: Santa Barbara Cottage Hospital
With more than 60years of use in catatonic patients, ECT has proven to be an effective and safe tool for the treatment of this frequent and sometimes forgotten syndrome. Initiation date: Mar 2019 --> Jun 2019
- | lorazepam / Generic mfg.
Phase classification: PSILOCD: Psilocybin for Treatment of Obsessive Compulsive Disorder (clinicaltrials.gov) - Feb 28, 2019
P1, N=15, Recruiting, Sponsor: University of Arizona
Initiation date: Mar 2019 --> Jun 2019 Phase classification: P2 --> P1
- | gabapentin / Generic mfg.
Trial completion date, Trial primary completion date: Gabapentin for Alcohol Withdrawal Syndrome (clinicaltrials.gov) - Feb 27, 2019
P4, N=400, Recruiting, Sponsor: Mayo Clinic
Phase classification: P2 --> P1 Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Feb 2019 --> Feb 2021
- | lorazepam / Generic mfg.
Enrollment open: PSILOCD: Psilocybin for Treatment of Obsessive Compulsive Disorder (clinicaltrials.gov) - Feb 7, 2019
P2, N=15, Recruiting, Sponsor: University of Arizona
Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Feb 2019 --> Feb 2021 Not yet recruiting --> Recruiting
- | lorazepam / Generic mfg.
New P1 trial: Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity (clinicaltrials.gov) - Feb 4, 2019
P1, N=120, Completed, Sponsor: University Hospital, Bonn
- | ketamine / Generic mfg., phenobarbital / Generic mfg.
New P4 trial: PKAT: Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine (clinicaltrials.gov) - Dec 28, 2018
P4, N=222, Not yet recruiting, Sponsor: Santa Barbara Cottage Hospital
- | lorazepam / Generic mfg.
New P2 trial: Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care (clinicaltrials.gov) - Nov 28, 2018
P2, N=120, Not yet recruiting, Sponsor: Maria Pacella
- | lorazepam / Generic mfg., haloperidol / Generic mfg.
New P2/3 trial, Metastases: NCI-2018-02438: Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care (clinicaltrials.gov) - Nov 16, 2018
P2/3, N=206, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | lorazepam / Generic mfg., diazepam / Generic mfg., alprazolam / Generic mfg.
Trial completion: Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free) (clinicaltrials.gov) - Oct 16, 2018
P1, N=480, Completed, Sponsor: McMaster University
Not yet recruiting --> Recruiting Recruiting --> Completed
- | lorazepam / Generic mfg.
Trial initiation date: PSILOCD: Psilocybin for Treatment of Obsessive Compulsive Disorder (clinicaltrials.gov) - Oct 12, 2018
P2, N=15, Not yet recruiting, Sponsor: University of Arizona
Recruiting --> Completed Initiation date: Aug 2018 --> Jan 2019
- | clonazepam / Generic mfg., lorazepam / Generic mfg., fosphenytoin / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: LORACLOFT: Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus (clinicaltrials.gov) - Oct 11, 2018
P3, N=434, Completed, Sponsor: Assistance Publique - H
Initiation date: Aug 2018 --> Jan 2019 Recruiting --> Completed | Trial completion date: Jun 2017 --> Feb 2018 | Trial primary completion date: Jun 2017 --> Feb 2018
- | lorazepam / Generic mfg., dexmedetomidine / Generic mfg.
Trial completion, Trial completion date: MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status (clinicaltrials.gov) - Sep 11, 2018
P2, N=100, Completed, Sponsor: Vanderbilt University
Recruiting --> Completed | Trial completion date: Jun 2017 --> Feb 2018 | Trial primary completion date: Jun 2017 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Dec 2016
- | lorazepam / Generic mfg.
Trial completion: Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: (clinicaltrials.gov) - Sep 5, 2018
P2, N=98, Completed, Sponsor: St. Justine's Hospital
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Dec 2016 Active, not recruiting --> Completed
- | lorazepam / Generic mfg., diazepam / Generic mfg., alprazolam / Generic mfg.
Trial primary completion date: Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free) (clinicaltrials.gov) - Aug 15, 2018
P1, N=480, Recruiting, Sponsor: McMaster University
Active, not recruiting --> Completed Trial primary completion date: Apr 2018 --> Aug 2018
- | Recentin (cediranib) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jul 19, 2018
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2018 --> Aug 2018 Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | Gralise (gabapentin) / Alvogen
Trial termination: Stanford Accelerated Recovery Trial (START) (clinicaltrials.gov) - Jun 28, 2018
P3, N=422, Terminated, Sponsor: Stanford University
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Active, not recruiting --> Terminated; Trial met futility stopping point
- | Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jun 28, 2018
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Trial met futility stopping point Trial primary completion date: Jun 2018 --> Jun 2019
- | ketamine / Generic mfg.
Enrollment closed, Trial primary completion date: Treatment Resistant Depression (Pilot) (clinicaltrials.gov) - Jun 20, 2018
P=N/A, N=40, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jun 2018 --> Jun 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jun 2019
- | OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
Trial completion date, Trial primary completion date: OSDI: Oral Sedation During Cervical Dilator Placement (clinicaltrials.gov) - Jun 6, 2018
P4, N=60, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Oct 2018 --> Jul 2019 | Trial primary completion date: Sep 2018 --> Jun 2019
- | Onsolis (BEMA fentanyl) / Viatris, Collegium Pharma, NN1213 / Novo Nordisk
Trial primary completion date: Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD) (clinicaltrials.gov) - Jun 4, 2018
P=N/A, N=109, Active, not recruiting, Sponsor: University of Florida
Trial completion date: Oct 2018 --> Jul 2019 | Trial primary completion date: Sep 2018 --> Jun 2019 Trial primary completion date: May 2018 --> Dec 2019
- | NN1213 / Novo Nordisk
Phase classification: MEDEX: A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise (clinicaltrials.gov) - Jun 3, 2018
P4, N=31, Completed, Sponsor: Kirk Erickson, PhD
Trial primary completion date: May 2018 --> Dec 2019 Phase classification: P=N/A --> P4
- | lorazepam / Generic mfg.
Trial initiation date: PSILOCD: Psilocybin for Treatment of Obsessive Compulsive Disorder (clinicaltrials.gov) - May 2, 2018
P2, N=15, Not yet recruiting, Sponsor: University of Arizona
Phase classification: P=N/A --> P4 Initiation date: Jan 2018 --> Aug 2018
- | lorazepam / Generic mfg.
Trial completion date, Trial primary completion date: Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: (clinicaltrials.gov) - Apr 18, 2018
P2, N=96, Active, not recruiting, Sponsor: St. Justine's Hospital
Initiation date: Jan 2018 --> Aug 2018 Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Head-to-Head: Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation (clinicaltrials.gov) - Apr 6, 2018
P4, N=2, Terminated, Sponsor: University of Arkansas
Trial completion date: Dec 2017 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018 N=140 --> 2 | Trial completion date: Aug 2019 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Apr 2018; Sponsor Withdrawal
- | Recentin (cediranib) / AstraZeneca
Trial completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Mar 12, 2018
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
N=140 --> 2 | Trial completion date: Aug 2019 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Apr 2018; Sponsor Withdrawal Trial completion date: Jun 2018 --> Jun 2019
- | New trial, Surgery: Post Operative Pain Control After Pediatric Hip Surgery (clinicaltrials.gov) - Feb 19, 2018
P=N/A, N=42, Completed, Sponsor: Seattle Children's Hospital
- | OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
Trial primary completion date: OSDI: Oral Sedation During Cervical Dilator Placement (clinicaltrials.gov) - Jan 29, 2018
P4, N=60, Recruiting, Sponsor: Johns Hopkins University
Trial completion date: Jun 2018 --> Jun 2019 Trial primary completion date: Feb 2018 --> Sep 2018
- Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Phase classification: ADASUVE-Lorazepam Drug-Drug Interaction (clinicaltrials.gov) - Dec 13, 2017
P4, N=22, Completed, Sponsor: Alexza Pharmaceuticals, Inc.
Trial primary completion date: Feb 2018 --> Sep 2018 Phase classification: P1 --> P4
- | lorazepam / Generic mfg.
Enrollment closed: Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: (clinicaltrials.gov) - Nov 30, 2017
P2, N=96, Active, not recruiting, Sponsor: St. Justine's Hospital
Phase classification: P1 --> P4 Recruiting --> Active, not recruiting
- | lorazepam / Generic mfg., diazepam / Generic mfg., alprazolam / Generic mfg.
Enrollment open, Trial initiation date: Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free) (clinicaltrials.gov) - Nov 20, 2017
P1, N=480, Recruiting, Sponsor: McMaster University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Apr 2017
- | Enrollment change, Trial termination, Trial primary completion date, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Oct 19, 2017
P3, N=407, Terminated, Sponsor: Hannover Medical School
Not yet recruiting --> Recruiting | Initiation date: Sep 2017 --> Apr 2017 N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Enrollment open, Head-to-Head: Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation (clinicaltrials.gov) - Oct 19, 2017
P4, N=140, Recruiting, Sponsor: University of Arkansas
N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- | lorazepam / Generic mfg.
Enrollment open: Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: (clinicaltrials.gov) - Oct 18, 2017
P2, N=96, Recruiting, Sponsor: St. Justine's Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | lorazepam / Generic mfg.
New P2 trial: PSILOCD: Psilocybin for Treatment of Obsessive Compulsive Disorder (clinicaltrials.gov) - Oct 4, 2017
P2, N=15, Not yet recruiting, Sponsor: University of Arizona
- | Onsolis (BEMA fentanyl) / Viatris, Collegium Pharma
Phase classification, Trial primary completion date: Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD) (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=109, Active, not recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Phase classification: P1 --> P=N/A | Trial primary completion date: Apr 2017 --> May 2018
- | lorazepam / Generic mfg.
New P4 trial: PAVE: Assessment of Valproate on Ethanol Withdrawal (clinicaltrials.gov) - Jul 31, 2017
P4, N=210, Recruiting, Sponsor: CAMC Health System
- | Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Trial initiation date, Trial primary completion date, Head-to-Head: Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation (clinicaltrials.gov) - Jul 11, 2017
P4, N=140, Not yet recruiting, Sponsor: University of Arkansas
Phase classification: P1 --> P=N/A | Trial primary completion date: Apr 2017 --> May 2018 Initiation date: May 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019
- | OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
Enrollment open: OSDI: Oral Sedation During Cervical Dilator Placement (clinicaltrials.gov) - Jul 2, 2017
P4, N=60, Recruiting, Sponsor: Johns Hopkins University
Initiation date: May 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019 Not yet recruiting --> Recruiting
- | dextromethorphan / Generic mfg.
Trial completion: Dextromethorphan to Treat Patients With Voice Spasms (clinicaltrials.gov) - Jun 30, 2017
P1, N=65, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting --> Recruiting Recruiting --> Completed